Evidence map›Paper›PMID 35903681›Full record

ArticleFrontiers in oncology2022

GPR12 Inhibits Apoptosis in Epithelial Ovarian Cancer

Lu Wang, Da Yang, Yao Zhang, Yisheng Jiao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lu WangDepartment of General Medicine, Liaoning Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Da YangDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Yao ZhangDepartment of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, China.
Yisheng JiaoDepartment of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies in women worldwide. G protein-coupled receptor 12 (GPR12) is a member of G protein-coupled receptors (GPCRs) and plays an important role in the regulation of cell proliferation and survival. However, its role in EOC is underappreciated. In this study, we found that GPR12 is highly expressed in the EOC tissues and can be an ideal biomarker to predict the prognosis of patients with EOC. GPR12 knockdown obviously inhibits the proliferation of EOC cells by inducing cellular apoptosis

Indexed as

apoptosisEOC (epithelial ovarian cancer)ERK1/2 signalingGPR12proliferation

Identifiers

PMID35903681
PMCPMC9316591
OpenAlexW4285094265

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.